TIL — Instil Bio, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1789769 ·
Last close
$7.12
Market Cap
$48.29M
52W High
$8.33
52W Low
$7.05
ADV30
13,087
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -6,018,000 | -4,204,000 | 200,428,000 | 5,022,000 | 89,730,000 |
| Dec 2025 | 0 | — | -9,557,000 | -8,191,000 | 203,523,000 | 6,638,000 | 89,657,000 |
| Sep 2025 | 0 | — | -15,022,000 | -13,587,000 | 211,768,000 | 5,801,000 | 91,346,000 |
| Jun 2025 | 0 | — | -12,900,000 | -21,394,000 | 230,986,000 | 7,688,000 | 99,316,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-33,761,000
Investing CF
$15,548,000
Financing CF
$7,060,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-10.19
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-730,692,000
Inventory
—
Receivables
$28,000
ST Investments
$69,549,000
EBIT TTM
$-42,077,000
Pretax Income TTM
$-47,376,000
Interest Exp TTM
$5,299,000
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -51,959,000 | -71,372,000 | 203,523,000 | 89,657,000 | — | -36,619,000 |
| Dec 2024 | 0 | -56,048,000 | -74,135,000 | 263,567,000 | 94,131,000 | — | -55,696,000 |
| Dec 2023 | 0 | -87,157,000 | -156,087,000 | 325,630,000 | 99,801,000 | — | -82,029,000 |
| Dec 2022 | 0 | -203,291,000 | -223,177,000 | 482,128,000 | 118,523,000 | — | -180,164,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-189,682,000
OpCashFlow TTM
$0
Assets (Latest)
$263,567,000
Forward EPS
$-14.64
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BKHA | Black Hawk Acquisition Corp | $48.93M | $11.78 | — |
| ATYR | aTYR PHARMA INC | $47.65M | $0.49 | — |
| SCLX | Scilex Holding Co | $46.87M | $6.66 | — |
| INMB | Inmune Bio, Inc. | $46.52M | $1.75 | — |
| TCRX | TScan Therapeutics, Inc. | $45.38M | $0.74 | — |
News headlines (Yahoo Finance, 1h cache)
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-15 11:00 · Yahoo
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
2026-03-27 11:00 · Yahoo
CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround
2026-02-03 15:20 · Yahoo
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
2026-02-03 15:06 · Yahoo
Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco
2026-01-06 12:00 · Yahoo
Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
2025-11-13 12:00 · Yahoo
Tumor Infiltrating Lymphocytes Therapy Market Research Report 2025-2030: Market Driven by Active R&D from Iovance Biotherapeutics, Juncell Therapeutics, Biosyngen, and Instil Bio
2025-10-21 09:34 · Yahoo
Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
2025-09-10 11:00 · Yahoo
Instil Bio, Inc. (NASDAQ:TIL) is definitely on the radar of institutional investors who own 36% of the company
2025-08-16 12:23 · Yahoo
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
2025-08-13 10:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.